Compare MUX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | PGEN |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | Canada | United States |
| Employees | 1432 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | MUX | PGEN |
|---|---|---|
| Price | $21.84 | $4.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $26.63 | $8.33 |
| AVG Volume (30 Days) | 1.0M | ★ 3.3M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $37.86 | $1,115.92 |
| Revenue Next Year | $31.10 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.25 | $1.28 |
| 52 Week High | $29.70 | $5.47 |
| Indicator | MUX | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 55.30 |
| Support Level | $20.43 | $3.96 |
| Resistance Level | $26.30 | $4.40 |
| Average True Range (ATR) | 1.25 | 0.27 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 23.39 | 46.74 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.